GCIA
FSTX

Gabelli & Co Investment Advisers’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-142,110
Closed -$898K – 295
2022
Q4 		$898K Sell
142,110
-4,990
-3% -$27.6K 0.19% 84
2022
Q3 		$753K Buy
147,100
+31,450
+27% +$197K 0.1% 150
2022
Q2 		$724K Buy
+115,650
New +$389K 0.09% 163

Gabelli & Co Investment Advisers's FSTX Position: Q1 2023 in Review

Gabelli & Co Investment Advisers sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 142,110 shares — an estimated $898K sold.

Gabelli & Co Investment Advisers first reported a position in FSTX in Q2 2022 and held it in 3 quarters. The position peaked at $898K in Q4 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

  • Gabelli & Co Investment Advisers reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 142,110 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $898K.
  • Gabelli & Co Investment Advisers first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Gabelli & Co Investment Advisers's F-star Therapeutics, Inc. Common Stock position peaked at $898K in Q4 2022.
  • 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2023, filed 12 May 2023.